Arsenic Trioxide Affects the Proliferation of Gastric Cancer Cells through MiR-885-5p/CDC73 Axis
Background: To explore Arsenic trioxide (As2O3) and its regulated miR-885-5p/CDC73 signaling pathway involved in the development of gastric cancer.
Methods: Fifty-two healthy patients and patients with gastric cancer were enrolled 2019-2020 in He Xian Memorial Hospital, Guangzhou, China. The patients with gastric cancer were divided into control group and As2O3 administration group. After 2 courses of treatment, their peripheral blood was collected to analyze the therapeutic effect. miR-885-5p expression in peripheral blood was analyzed by qRT-PCR. As2O3 was added into MGC-803 gastric cancer cell line at 0, 10, 20, 40 and 80 μmol/L. The proliferation rate and 48h IC50 value of gastric cancer cells were investigated by CCK-8, and the effect of As2O3 on miR-885-5p expression in the cells was analyzed.
Results: After 4 weeks of treatment, the objective efficiency of control group and As2O3 administration group was 17.3% and 13.4%, respectively, without significant statistical difference. The overall benefit rate of As2O3 administration group was significantly higher than that of the normal treatment group (P=0.049). qRT-PCR experiment results found that miR-885-5p significantly highly expressed in peripheral blood in the As2O3 administration group, while miR-885-5p in gastric cancer was lower compared with normal people. Adding As2O3 to the gastric cancer cells could significantly inhibit miR-885-5p expression, while miR-885-5p in gastric cancer cells affected cell expression by targeted regulation, affecting cell proliferation.
Conclusion: As2O3 may be used as a drug treatment program for gastric cancer, and mainly regulates the proliferation of gastric cancer cells by affecting the miR-885-5p/CDC73 target axis to participate in the development of gastric cancer.
2. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020). Gastric cancer. Lancet, 396: 635-648.
3. Das M (2017). Arsenic trioxide consolida-tion in APL. Lancet Oncol, 18: e517.
4. Hoonjan M, Jadhav V, Bhatt P (2018). Ar-senic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem, 23: 313-329.
5. Wang QQ, Jiang Y, Naranmandura H (2020). Therapeutic strategy of arsenic tri-oxide in the fight against cancers and other diseases. Metallomics, 12: 326-336.
6. Xiao YF, Liu SX, Wu DD, Chen X, Ren LF (2006). Inhibitory effect of arsenic triox-ide on angiogenesis and expression of vascular endothelial growth factor in gas-tric cancer. World J Gastroenterol, 12: 5780-5786.
7. Zheng Y, Zhou M, Ye A, Li Q, Bai Y, Zhang Q (2010). The conformation change of Bcl-2 is involved in arsenic tri-oxide-induced apoptosis and inhibition of proliferation in SGC7901 human gas-tric cancer cells. World J Surg Oncol, 8: 31.
8. Jia Y, Liu D, Xiao D, et al (2013). Expres-sion of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells. PLoS One, 8: e54774.
9. Bhatti GK, Khullar N, Sidhu IS, et al (2021). Emerging role of non-coding RNA in health and disease. Metab Brain Dis, 36: 1119-1134.
10. Xu F, Yan JJ, Gan Y, Chang Y, Wang HL, He XX, Zhao Q (2019). miR-885-5p Negatively Regulates Warburg Effect by Silencing Hexokinase 2 in Liver Cancer. Mol Ther Nucleic Acids, 18: 308-319.
11. Liu Y, Bao Z, Tian W, Huang G (2019). miR-885-5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β-catenin. Oncol Lett, 17: 1996-2004.
12. Su M, Qin B, Liu F, Chen Y, Zhang R (2018). miR-885-5p upregulation pro-motes colorectal cancer cell proliferation and migration by targeting suppressor of cytokine signaling. Oncol Lett, 16: 65-72.
13. Lixin S, Wei S, Haibin S, Qingfu L, Tiemin P (2020). miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholan-giocarcinoma. Mol Carcinog, 59: 1371-1381.
14. Seymour L, Bogaerts J, Perrone A, et al (2017). iRECIST: guidelines for response criteria for use in trials testing immuno-therapeutics. Lancet Oncol, 18: e143-e152.
15. Mao D, Zhang X, Wang Z, Xu G, Zhang Y (2022). TMEM97 is transcriptionally acti-vated by YY1 and promotes colorectal cancer progression via the GSK-3β/β-catenin signaling pathway. Hum Cell, 35: 1535-1546.
16. Chen GQ, Zhu J, Shi XG, et al (1996). In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apop-tosis with downregulation of Bcl-2 ex-pression and modulation of PML-RAR alpha/PML proteins. Blood, 88: 1052-61.
17. Hoonjan M, Jadhav V, Bhatt P (2018). Ar-senic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem, 23: 313-329.
18. Wahiduzzaman M, Ota A, Hosokawa Y (2020). Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Triox-ide. Curr Cancer Drug Targets, 20: 115-129.
19. Chang KJ, Yin JZ, Huang H, Li B, Yang MH (2020). Arsenic trioxide inhibits the growth of cancer stem cells derived from small cell lung cancer by downregulating stem cell-maintenance factors and induc-ing apoptosis via the Hedgehog signaling blockade. Transl Lung Cancer Res, 9: 1379-1396.
20. Shi Y, Cao T, Huang H, et al (2017). Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells. Cell Cycle, 16: 2396-2403.
21. Wang L, Wang R, Fan L, et al (2017). Arse-nic trioxide is an immune adjuvant in liver cancer treatment. Mol Immunol, 81: 118-126.
22. Abudoureyimu A, Muhemaitibake A (2017). Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP. Eur Rev Med Pharmacol Sci, 21: 612-617.
23. Liu Y, Zhang W, Zhang X, Qi Y, Huang D, Zhang Y (2011). Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix met-alloproteinase-2 pathway. Exp Biol Med (Maywood), 236: 592-597.
24. Zhang Z, Yin J, Yang J, et al (2016). miR-885-5p suppresses hepatocellular carci-noma metastasis and inhibits Wnt/β-catenin signaling pathway. Oncotarget, 7: 75038-75051.
25. Jin X, Wang Z, Pang W, et al (2018). Upreg-ulated hsa_circ_0004458 Contributes to Progression of Papillary Thyroid Carci-noma by Inhibition of miR-885-5p and Activation of RAC1. Med Sci Monit, 24: 5488-5500.
26. Li S, Sun MY, Su X (2019). MiR-885-5p promotes gastric cancer proliferation and invasion through regulating YPEL1. Eur Rev Med Pharmacol Sci, 23: 7913-7919.
27. Jiang Z, Cui H, Zeng S, Li L (2021). miR-885-5p Inhibits Invasion and Metastasis in Gastric Cancer by Targeting Malic En-zyme 1. DNA Cell Biol, 40: 694-705.
28. Wang L, Zhang Q, You Q (2021). Targeting the HSP90-CDC37-kinase chaperone cy-cle: A promising therapeutic strategy for cancer. Med Res Rev, 42: 156-182.
29. Müller JP, Klempnauer KH (2021). The CDC37-HSP90 chaperone complex co-translationally degrades the nascent ki-nase-dead mutant of HIPK2. FEBS Lett, 595: 1559-1568.
|Issue||Vol 52 No 1 (2023)|
|Gastric cancer Arsenic trioxide Immunology Cell proliferation|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|